Pfizer Inc.
PD-1/PD-L1 inhibitors for the treatment of cancer
Last updated:
Abstract:
The invention relates to methods of treating cancer in a subject, comprising administering to the subject a therapeutically effective amount of an inhibitor of the interaction between the PD-1 receptor and its ligand PD-L1.
Status:
Grant
Type:
Utility
Filling date:
23 Feb 2016
Issue date:
13 Oct 2020